From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program
- 1 day ago
- 1 min read
He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.
.png){kind=logo}